Pogorielova Oksana S, Korniienko Viktoriia V, Chumachenko Yaroslav D, Obukhova Olha A, Martsovenko Igor, Harbuzova Viktoriia Yu
Department of Internal Medicine with Center of Respiratory Medicine, Sumy State University, Sumy 40007, Ukraine.
Biomedical Research Center, Sumy State University, Sumy 40018, Ukraine.
Cardiol Res Pract. 2022 Apr 11;2022:2067632. doi: 10.1155/2022/2067632. eCollection 2022.
Coronary artery disease (CAD) is one of the leading causes of death in Europe. It is known that atherosclerosis is the primary risk factor of CAD development. MMP-9 is involved in all stages of atherosclerosis and thus may contribute to CAD emergence. To investigate the influence of MMP-9 on the (CAD) development 25 patients with intact coronary arteries (CA), 40 patients with acute coronary syndrome (ACS), and 63 patients with chronic coronary syndrome (CCS) were enrolled in the study. Real-time PCR was carried out for genotyping on the rs17567-polymorphic locus, and ELISA study was performed to measure the MMP-9 plasma concentration. It was found the lower risk of MI occurrence for AG-carriers ( =0.023; OR = 0.299, 95% CI = 0.106-0.848) in Ukrainian population.
冠状动脉疾病（CAD）是欧洲主要的死亡原因之一。已知动脉粥样硬化是CAD发生的主要危险因素。基质金属蛋白酶-9（MMP-9）参与动脉粥样硬化的各个阶段，因此可能导致CAD的出现。为了研究MMP-9对CAD发展的影响，本研究纳入了25例冠状动脉完整（CA）的患者、40例急性冠状动脉综合征（ACS）患者和63例慢性冠状动脉综合征（CCS）患者。对rs17567多态性位点进行基因分型的实时聚合酶链反应（PCR），并进行酶联免疫吸附测定（ELISA）研究以测量血浆MMP-9浓度。发现在乌克兰人群中，AG携带者发生心肌梗死（MI）的风险较低（P = 0.023；比值比[OR] = 0.299，95%置信区间[CI] = 0.106 - 0.848）。
